Mar 21, 2019
BioLineRx to Report Annual 2018 Results on March 28, 2019
Mar 14, 2019
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
Feb 12, 2019
Frost & Sullivan Publishes Immediate Report on BiolineRx
Feb 05, 2019
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
Feb 04, 2019
BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants
Feb 04, 2019
BioLineRx Receives Orphan Drug Designation From the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer
Jan 02, 2019
BioLineRx to Present at the 2019 Biotech Showcase
Dec 06, 2018
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
Nov 20, 2018
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
Nov 01, 2018
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
Oct 03, 2018
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Aug 30, 2018
BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
Aug 06, 2018
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
Jun 13, 2018
BioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
Jun 11, 2018
Compugen Announces the Appointment of New Board Members
May 22, 2018
BioLineRx Reports First Quarter 2018 Financial Results
May 16, 2018
BioLineRx to Report First Quarter 2018 Results on May 22, 2018
May 16, 2018
BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
Mar 26, 2018
BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
Mar 26, 2018
Frost & Sullivan Publishes Update Coverage Report on BiolineRx Ltd.: Continued advancement and execution of BiolineRx's lead oncology project - BL-8040; sufficient funds to support clinical strategy; stock target price remains at NIS 5.15